secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zura Bio Ltd (ZURA)
CIK:        0001855644
Form:       8-K
Filed at:   2023-12-06T23:59:59+00:00
Accession:  0001104659-23-124000
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zura Bio appoints Dr. Kiran Nistala as EVP, effective Nov 27, 2023
------------------------------------------------------------------

- Dr. Nistala appointed Executive Vice President, effective November 27, 2023.
- Annual base salary of GBP £320,000; eligible for discretionary bonus targeting 40% of base.
- Company will recommend grant of 350,000 share options under 2023 Equity Incentive Plan.
- Options vest 1/4 on first anniversary, then 1/36 monthly over 36 months; full vest at 4 years.
- Dr. Nistala previously VP late-stage clinical development at AstraZeneca; also held senior roles at GSK.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855644/000110465923124000/0001104659-23-124000-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855644/000110465923124000/tm2332309d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-124000

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer